Immunome (IMNM)
(Delayed Data from NSDQ)
$14.99 USD
-0.30 (-1.96%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $14.99 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
IMNM 14.99 -0.30(-1.96%)
Will IMNM be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for IMNM based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for IMNM
Immunome, Inc. (IMNM) Reports Q2 Loss, Misses Revenue Estimates
Cartesian Therapeutics, Inc. (RNAC) Q2 Earnings and Revenues Top Estimates
IMNM: What are Zacks experts saying now?
Zacks Private Portfolio Services
Cytek Biosciences, Inc. (CTKB) Reports Q2 Loss, Lags Revenue Estimates
Immunome, Inc. (IMNM) Reports Q1 Loss, Misses Revenue Estimates
Analysts Estimate Immunome, Inc. (IMNM) to Report a Decline in Earnings: What to Look Out for
Other News for IMNM
TD Cowen Sticks to Its Buy Rating for Immunome (IMNM)
Immunome to Present Updated Results for RINGSIDE Phase 2 Trial of AL102 for the Treatment of Desmoid Tumors at the European Society for Medical Oncology (ESMO) Congress 2024
Redmile Group, LLC Expands Stake in Atara Biotherapeutics Inc
Immunome (IMNM) Shares Cross Above 200 DMA
Immunome to Present at Morgan Stanley 22nd Annual Global Healthcare Conference